Von Hoff DD, Layard MW, Basa P, Davis HL, von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7. https://doi.org/10.7326/0003-4819-91-5-710.
Article
Google Scholar
Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D’Ascenzo F, Malavasi V, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112:1980–4. https://doi.org/10.1016/j.amjcard.2013.08.026.
Article
CAS
PubMed
Google Scholar
Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single Centre experience. Eur J Heart Fail. 2018;20(5):898–906. https://doi.org/10.1002/ejhf.1049.
Article
CAS
PubMed
Google Scholar
Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84. https://doi.org/10.1056/NEJM200004133421502.
Article
CAS
PubMed
Google Scholar
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. https://doi.org/10.1093/eurheartj/ehw211.
Article
PubMed
Google Scholar
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54. https://doi.org/10.1161/01.CIR.0000130926.51766.CC.
Article
CAS
PubMed
Google Scholar
Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82(4):218–22. https://doi.org/10.1007/s00277-003-0615-3.
Article
CAS
PubMed
Google Scholar
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of Anthracycline Cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8. https://doi.org/10.1161/CIRCULATIONAHA.114.013777.
Article
CAS
PubMed
Google Scholar
Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837–49. https://doi.org/10.1161/CIRCULATIONAHA.104.500546.
Article
PubMed
Google Scholar
Mercurio V, Pirozzi F, Lazzarini E, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail. 2016;22(6):449–58. https://doi.org/10.1016/j.cardfail.2016.04.008.
Article
CAS
PubMed
Google Scholar
Teske AJ, Linschoten M, Kamphuis JAM, Naaktgeboren WR, Leiner T, van der Wall E, et al. Cardio-oncology: an overview on outpatient management and future developments. Neth Hear J. 2018;26(11):521–32. https://doi.org/10.1007/s12471-018-1148-7.
Article
CAS
Google Scholar
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. https://doi.org/10.1093/eurheartj/ehw128.
Article
PubMed
Google Scholar
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after Cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–93. https://doi.org/10.1016/j.echo.2014.07.012.
Article
PubMed
PubMed Central
Google Scholar
Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams J, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood Cancer: report from the cardiovascular disease task force of the Children’s oncology group. Pediatrics. 2008;121(2):e387–96. https://doi.org/10.1542/peds.2007-0575.
Article
PubMed
Google Scholar
Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67(25):2996–3010. https://doi.org/10.1016/j.jacc.2016.03.590.
Article
PubMed
Google Scholar
Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547–58. https://doi.org/10.1038/nrcardio.2015.65.
Article
CAS
PubMed
Google Scholar
Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. https://doi.org/10.1016/j.jacc.2009.03.095.
Article
CAS
PubMed
Google Scholar
Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850–8. https://doi.org/10.1093/eurheartj/ehv727.
Article
PubMed
Google Scholar
Ferreira de Souza T, Quinaglia AC, Silva T, Osorio Costa F, Sha R, Neilan TG, Velloso L, et al. Anthracycline therapy is associated with Cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging. 2018;11(8):1045–55. https://doi.org/10.1016/j.jcmg.2018.05.012.
Article
PubMed
Google Scholar
Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, et al. Left ventricular mass in patients with a cardiomyopathy after treatment with Anthracyclines. Am J Cardiol. 2012;110(11):1679–86. https://doi.org/10.1016/j.amjcard.2012.07.040.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jordan JH, Castellino SM, Meléndez GC, Klepin HD, Ellis LR, Lamar Z, et al. Left ventricular mass change after Anthracycline chemotherapy. Circ Heart Fail. 2018;11(7):e004560. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004560.
Article
CAS
PubMed
PubMed Central
Google Scholar
Narayan HK, Finkelman B, French B, Plappert T, Hyman D, Smith AM, et al. Detailed echocardiographic Phenotyping in breast Cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation. 2017;135(15):1397–412. https://doi.org/10.1161/CIRCULATIONAHA.116.023463.
Article
PubMed
PubMed Central
Google Scholar
Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, et al. Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast Cancer treated with Anthracyclines, Taxanes, and Trastuzumab. J Am Soc Echocardiogr. 2015;28(5):509–14. https://doi.org/10.1016/j.echo.2015.02.001.
Article
PubMed
Google Scholar
Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood Cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30(23):2876–84. https://doi.org/10.1200/JCO.2011.40.3584.
Article
PubMed
PubMed Central
Google Scholar
Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629–36. https://doi.org/10.1200/JCO.2005.12.121.
Article
CAS
PubMed
Google Scholar
Jones DN, Jordan JH, Meléndez GC, Lamar Z, Thomas A, Kitzman DW, et al. Frequency of transition from stage a to stage B heart failure after initiating potentially Cardiotoxic chemotherapy. JACC Heart Fail. 2018;6(12):1023–32. https://doi.org/10.1016/j.jchf.2018.08.005.
Article
PubMed
PubMed Central
Google Scholar
Echouffo-Tcheugui JB, Ergou S, Butler J, Yancy CW, Fonarow GC. Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis. JACC Heart Fail. 2016;4(4):237–48. https://doi.org/10.1016/j.jchf.2015.09.015.
Article
PubMed
Google Scholar
Linschoten M, Teske AJ, Cramer MJ, van der Wall E, Asselbergs FW. Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ Genom Precis Med. 2018;11(1):e001753. https://doi.org/10.1161/CIRCGEN.117.001753.
Article
CAS
PubMed
Google Scholar
Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, et al. Genetic variants associated with Cancer therapy-induced cardiomyopathy. Circulation. 2019;140(1):31–41. https://doi.org/10.1161/CIRCULATIONAHA.118.037934.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pituskin E, Haykowsky M, McNeely M, Mackey J, Chua N, Paterson I. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN). BMC Cancer. 2016;16:733.
PubMed
PubMed Central
Google Scholar
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. https://doi.org/10.1016/j.annonc.2019.10.023.
Article
CAS
PubMed
Google Scholar
Ammon M, Arenja N, Leibundgut G, Buechel RR, Kuster GM, Kaufmann BA, et al. Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice. J Card Fail. 2013;19(9):629–34. https://doi.org/10.1016/j.cardfail.2013.07.007.
Article
PubMed
Google Scholar
Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. 2017;18(8):e445–56. https://doi.org/10.1016/S1470-2045(17)30535-1.
Article
CAS
PubMed
Google Scholar